Could IL-25 be a potential therapeutic target for intestinal inflammatory diseases?. (February 2023)

• Record Type: Journal Article
• Authors: Chen, Jie; Wang, Yingshu; Shen, Lan; Xiu, Yanfeng; Wang, Bing
• Is Part Of: Cytokine & growth factor reviews. Volume 69(2023)
• Page Start: 43
• Page End: 50
• Publication Date: 2023-02
• Subjects: IL-25 -- Type-2 immunity -- Inflammatory bowel disease; IBD inflammatory bowel disease -- UC ulcerative colitis -- CD Crohn's disease -- DSS dextran sulfate sodium -- TNBS 2, 4, 6-trinitrobenzene sulfonic acid -- RFP red fluorescent protein -- MARS-seq massively parallel single-cell RNA-sequencing -- mTEC medullary tuft epithelial cell -- GNAT3 guanine nucleotide-binding protein G(t) subunit α3 -- Plcβ2 phospholipase C β2 -- Ip3r2 inositol triphosphate receptor type 2 -- TRPM5 transient receptor potential cation channel subfamily M member 5 -- rIL-25 recombinant IL-25 -- ILC2s innate lymphoid cells 2 -- CLPs common lymphoid progenitors -- CysLTs cysteinyl leukotrienes -- CDI Clostridium difficile infection -- MHC II major histocompatibility complex II -- OXA oxazolone -- DAI disease activity index -- TGF-β transforming growth factor-β -- miR microRNA -- MSCs mesenchymal stem cells; Cytokines -- Periodicals; 571.84
• DOI: 10.1016/j.cytogfr.2022.07.001
• Languages: English
• ISSNs: 1359-6101

Abstract

Abstract: As a member of the IL-17 cytokine family, IL-25 (also called IL-17E) induces and sustains type 2 immunity. IL-25, which is mainly produced by intestinal epithelial cells, has been gradually investigated in recent years for its function in intestinal inflammation but is not yet fully understood. This review summarizes the expression and function of IL-25 in the intestine, especially the progression of its regulatory role on type 2 immunity-related cells. Finally, we discuss the dual role of IL-25 based on inflammatory bowel disease to inform research on targeting IL-25 for the treatment of intestinal inflammatory diseases. Graphical Abstract: ga1 Highlights: IL-25 is predominantly expressed by tuft cells in the intestine and its expression is increased by parasitic stimulation. IL-25 regulates ILC and Th2 cells to trigger type-2 immunity. IL-25 has a dual role in inflammatory bowel diseases and therefore may be a therapeutic target.